3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Sarcoma
3
Head & Neck
3
Thoracic
2
Genitourinary
2
Gastrointestinal
2
Endocrine
2
Dermatologic
2
CNS
2
Breast
2
NET
1
Lymphoid
1
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Breast Neoplasms
12
Neoplasms
8
Multiple Myeloma
8
Melanoma
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Hematologic Neoplasms
6
Urinary Bladder Neoplasms
5
Prostatic Neoplasms
5
Neoplasm Metastasis
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Thyroid Neoplasms
4
Sarcoma
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Head and Neck Neoplasms
4
Endometrial Neoplasms
4
Adenocarcinoma
4
Urothelial Cancer
3
Thyroid Cancer, Papillary
3
Stomach Neoplasms
3
Salivary Gland Neoplasms
3
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Neurofibromatosis 1
3
Neurofibroma, Plexiform
3
Neuroendocrine Tumors
3
Interventions
entrectinib
2
larotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has announcements
×
Salivary Gland Neoplasms
×
90 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA